open access
Diagnosis and management of a patient with idiopathic macular telangiectasia type 2
Affiliations- Laser Plus Eye, Nea Smyrni, Athens, Greece
open access
Abstract
Abstract
Keywords
MacTel, MacTel 2, macular telangiectasia type 2
About this articleTitle
Diagnosis and management of a patient with idiopathic macular telangiectasia type 2
Journal
Issue
Article type
Case report
Pages
83-86
Published online
2017-12-28
Page views
813
Article views/downloads
1069
DOI
Bibliographic record
Ophthalmol J 2017;2(3):83-86.
Keywords
MacTel
MacTel 2
macular telangiectasia type 2
Authors
Ioannis Mallias
Panagiota Mylova
Anastasia Tassiopoulou
References (18)- Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol. 2013; 58(6): 536–559.
- Clemons TE, Gillies MC, Chew EY, et al. Macular Telangiectasia Project Research Group. Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3. Ophthalmic Epidemiol. 2013; 20(2): 109–113.
- Sallo FB, Leung I, Zeimer M, et al. MacTel Study Group. Abnormal retinal reflectivity to short-wavelength light in type 2 idiopathic macular telangiectasia. Retina. 2017 [Epub ahead of print].
- Heeren TFC, Clemons T, Scholl HPN, et al. Progression of vision loss in macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2015; 56(6): 3905–3912.
- Sallo FB, Leung I, Clemons TE, et al. MacTel CNTF Research Group. Correlation of structural and functional outcome measures in a phase one trial of ciliary neurotrophic factor in type 2 idiopathic macular telangiectasia. Retina. 2017 [Epub ahead of print].
- Gonzalez MA, Shechtman D, Haynie JM, et al. Unveiling idiopathic macular telangiectasia: clinical applications of optical coherence tomography angiography. Eur J Ophthalmol. 2017; 27(4): e129–e133.
- Chidambara L, Gadde SGK, Yadav NK, et al. Characteristics and quantification of vascular changes in macular telangiectasia type 2 on optical coherence tomography angiography. Br J Ophthalmol. 2016; 100(11): 1482–1488.
- Toto L, Di Antonio L, Mastropasqua R, et al. Multimodal imaging of macular telangiectasia type 2: Focus on vascular changes using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016; 57(9): OCT268–OCT276.
- Alkin Z, Yilmaz I, Ozkaya A, et al. Anti-vascular endothelial growth factor treatment for proliferative macular telangiectasia type 2. Middle East Afr J Ophthalmol. 2016; 23(2): 222–224.
- Chhablani J, Dedhia CJ, Peguda HK, et al. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina. 2017; 37(10): 1859–1865.
- Aydoğan T, Erdoğan G, Ünlü C, et al. Intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia. Turk J Ophthalmol. 2016; 46(6): 270–273.
- Toygar O, Guess MG, Youssef DS, et al. Long-term outcomes of intravitreal bevacizumab therapy for subretinal neovascularization secondary to idiopathic macular telangiectasia type 2. Retina. 2016; 36(11): 2150–2157.
- Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 1982; 100(5): 769–780.
- Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993; 100(10): 1536–1546.
- Gamulescu MA, Walter A, Sachs H, et al. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008; 246(8): 1189–1193.
- Charbel Issa P, Finger RP, Kruse K, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol. 2011; 151(5): 876–886.e1.
- Wilson C. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Archives of Ophthalmology. 1992; 110(8): 1155.
- Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005; 80(2): 249–258.